We are comparing Athersys Inc. (NASDAQ:ATHX) and Akari Therapeutics Plc (NASDAQ:AKTX) on their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athersys Inc.	23.95M	8.85	26.06M	-0.21	0.00
Akari Therapeutics Plc	N/A	0.00	25.07M	-1.68	0.00

Table 1 highlights Athersys Inc. and Akari Therapeutics Plc’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 hightlights the net margins, return on assets and return on equity of the two companies.

	Net Margins	Return on Equity	Return on Assets
Athersys Inc.	-108.81%	-58.7%	-44.6%
Akari Therapeutics Plc	0.00%	-207.2%	-119%

Risk and Volatility

Athersys Inc. is 53.00% less volatile than Standard and Poor’s 500 because the company has a beta of 0.47. From a competition point of view, Akari Therapeutics Plc has a -3.96 beta which is 496.00% more volatile compared to Standard and Poor’s 500.

Liquidity

The Current Ratio and Quick Ratio of Athersys Inc. are 4.6 and 4.6 respectively. Its competitor Akari Therapeutics Plc’s Current Ratio is 2 and its Quick Ratio is 2. Athersys Inc. can pay off short and long-term obligations better than Akari Therapeutics Plc.

Institutional & Insider Ownership

Institutional investors held 23.7% of Athersys Inc. shares and 5.6% of Akari Therapeutics Plc shares. 2.1% are Athersys Inc.’s share held by insiders. Comparatively, insiders own roughly 57.08% of Akari Therapeutics Plc’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Athersys Inc.	1.97%	-2.52%	-19.69%	-22.89%	15.67%	7.64%
Akari Therapeutics Plc	0.51%	-8.94%	5.79%	-4.18%	-5.66%	16.57%

For the past year Athersys Inc. has weaker performance than Akari Therapeutics Plc

Summary

On 6 of the 9 factors Athersys Inc. beats Akari Therapeutics Plc.

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The companyÂ’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase 2 study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase 2 clinical study for treating patients with acute myocardial infarction; and, which is in Phase 1/2 clinical study for treating patients with acute respiratory distress syndrome, as well as completed Phase 1 clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients; and 5HT2c agonists for the treatment of obesity and other conditions. The company has license and collaboration agreements with Healios K.K. and Chugai Pharmaceuticals Co., Ltd. to develop and commercialize MultiStem cell therapy for ischemic stroke; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.